Pharma Mar SA (PHMMF)
94.60
0.00 (0.00%)
USD |
OTCM |
Oct 07, 16:00
Pharma Mar Enterprise Value : 1.499B for Oct. 7, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 07, 2026 | 1.499B |
| October 06, 2026 | 1.499B |
| October 05, 2026 | 1.499B |
| October 02, 2026 | 1.499B |
| October 01, 2026 | 1.499B |
| September 30, 2026 | 1.499B |
| September 29, 2026 | 1.499B |
| September 28, 2026 | 1.499B |
| September 25, 2026 | 1.499B |
| September 24, 2026 | 1.499B |
| September 23, 2026 | 1.499B |
| September 22, 2026 | 1.499B |
| September 21, 2026 | 1.499B |
| September 18, 2026 | 1.499B |
| September 17, 2026 | 1.499B |
| September 16, 2026 | 1.499B |
| September 15, 2026 | 1.499B |
| September 14, 2026 | 1.499B |
| September 11, 2026 | 1.499B |
| September 10, 2026 | 1.499B |
| September 09, 2026 | 1.499B |
| September 08, 2026 | 1.499B |
| September 04, 2026 | 1.499B |
| September 03, 2026 | 1.499B |
| September 02, 2026 | 1.499B |
| Date | Value |
|---|---|
| September 01, 2026 | 1.499B |
| August 31, 2026 | 1.499B |
| August 28, 2026 | 1.547B |
| August 27, 2026 | 1.547B |
| August 26, 2026 | 1.378B |
| August 25, 2026 | 1.378B |
| August 24, 2026 | 1.378B |
| August 21, 2026 | 1.378B |
| August 20, 2026 | 1.378B |
| August 19, 2026 | 1.378B |
| August 18, 2026 | 1.378B |
| August 17, 2026 | 1.378B |
| August 14, 2026 | 1.378B |
| August 13, 2026 | 1.378B |
| August 12, 2026 | 1.378B |
| August 11, 2026 | 1.378B |
| August 10, 2026 | 1.378B |
| August 07, 2026 | 1.378B |
| August 06, 2026 | 1.378B |
| August 05, 2026 | 1.378B |
| August 04, 2026 | 1.352B |
| August 03, 2026 | 1.352B |
| July 31, 2026 | 1.352B |
| July 30, 2026 | 1.352B |
| July 29, 2026 | 1.352B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Oryzon Genomics SA | 230.01M |
| Grifols SA | 13.87B |
| ACADIA Pharmaceuticals, Inc. | 2.500B |
| Alkermes Plc | 7.860B |
| Alnylam Pharmaceuticals, Inc. | 29.69B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.130M |
| Revenue (Quarterly) | 57.68M |
| Total Expenses (Quarterly) | 58.81M |
| EPS Diluted (Quarterly) | -0.0652 |
| Gross Profit Margin (Quarterly) | 86.21% |
| Profit Margin (Quarterly) | -1.96% |
| Earnings Yield | 3.95% |
| Operating Earnings Yield | 2.24% |
| Normalized Earnings Yield | 3.955 |